Barzolvolimab: Disease-Modifying Breakthrough for Refractory CSU
Barzolvolimab demonstrates sustained, disease-modifying efficacy in antihistamine-refractory chronic spontaneous urticaria.
Chronic spontaneous urticaria (CSU) remains a challenging condition for primary care physicians to manage, particularly when patients fail to respond to standard antihistamine regimens, but new clinical data presented at the
Unlike traditional therapies focus on blocking the downstream effects of inflammation, barzolvolimab addresses the underlying driver of CSU by targeting mast cells directly. “I believe barzolvolimab’s unique ability to target the underlying driver of CSU—the mast cell—resulted in unprecedented rapid, profound and durable complete responses in this large phase 2 study, with up to 51% of patients achieving a complete response, no itch or hives, at 12 weeks which continued to deepen over 52 weeks of treatment to up to 71% of patients,” stated lead investigator Martin Metz, MD, of Charité – Universitätsmedizin in Berlin.
In a phase 2 double-blind, placebo-controlled trial, investigators evaluated barzolvolimab in patients with antihistamine-refractory CSU. Participants were randomized to receive either 150 mg of the drug every 4 weeks or 300 mg every 8 weeks. By week 12, up to 51% of patients achieved a complete response, defined as the total absence of itch and hives. This response continued to improve over a year of treatment, with up to 71% of patients reaching complete response by week 52.
The severity of the disease in the study population underscores the drug's potential. At the start of the study, 70.9% of participants were classified as having severe disease. However, following 52 weeks of treatment, 87.3% of those who completed the protocol achieved a complete response, while the remaining 12.7% reached "well-controlled" status.
For primary care providers, the impact on a patient's daily functioning is often as critical as clinical metrics. The study utilized the Dermatology Life Quality Index (DLQI) to measure this impact. By week 76, 83.3% of patients reported a DLQI score of 0 or 1, indicating the disease no longer had any impact on their quality of life.
Perhaps the most significant finding for the medical community is barzolvolimab’s prolonged efficacy after the cessation of treatment. In an exploratory analysis of 48 participants who had well-controlled disease at week 52, investigators monitored their status through week 76, 7 months after their final dose.
At week 76, 81% of participants still maintained at least mild disease control, with 50% continuing to exhibit a complete response and 18.8% maintaining well-controlled disease. This sustained efficacy was observed even though the drug had cleared from the patients' systems and serum tryptase, a key mast cell biomarker, had normalized.
These findings suggest barzolvolimab does more than just suppress symptoms; it may modify the course of the disease. "The majority had a complete response 7 months after their last dose and for those who did experience disease return, it was generally mild," noted Metz.
For patients with severe CSU who have exhausted traditional antihistamine options, these results offer a new horizon of hope. The ability of a treatment to provide long-term, off-treatment control is a significant departure from current therapeutic models require continuous dosing to maintain suppression. As research moves forward, barzolvolimab stands as a potential first-in-class option could redefine the standard of care for refractory CS.
References:
- Barzolvolimab Provides Long-Term Improvements. Aaaai.org. Published February 10, 2026. Accessed February 27, 2026. https://www.aaaai.org/about/news/news/2026/barzolvolimab
- Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week DataMaurer, Marcus et al. Journal of Allergy and Clinical Immunology, Volume 155, Issue 2, AB431
